Burkholderia Pseudomallei Causing Bone and Joint Infections: A Clinical Update

• Published in: Infectious diseases and therapy Vol. 5; no. 1; pp. 17 - 29
• Main Authors: Raja, Nadeem Sajjad, Scarsbrook, Christine
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.03.2016; Springer Nature B.V
• Subjects: Bacterial infections; Bones; Burkholderia pseudomallei; Infectious Diseases; Internal Medicine; Joints; Medicine; Medicine & Public Health; Mycobacterium; Review; Melioidosis; Bone and joint infections; Burkholderia pseudomallei
• ISSN: 2193-8229; 2193-6382
• DOI: 10.1007/s40121-015-0098-2

Burkholderia pseudomallei ( B. pseudomallei ), a causative agent of an emerging infectious disease melioidosis, is endemic in the tropical regions of the world. Due to increased international travel, the infection is now also seen outside of the tropics. The majority of patients with identified risk factors such as diabetes mellitus, heavy alcohol use, malignancy, chronic lung and kidney disease, corticosteroid use, thalassemia, rheumatic heart disease, systemic lupus erythematosus and cardiac failure acquire this organism through percutaneous inoculation or inhalation. The clinical manifestations are variable, ranging from localized abscess formation to septicemia. Melioidotic bone and joint infections are rarely reported but are an established entity. The knee joint is the most commonly affected joint in melioidosis, followed by the ankle, hip and shoulder joints. Melioidosis should be in the differential diagnosis of bone and joint infections in residents or returning travelers from the endemic area. Melioidosis diagnosis is missed in many parts of the world due to the lack of awareness of this infection and limited laboratory training and diagnostic techniques. It also mimics other diseases such as tuberculosis. Delay in the diagnosis, or the initiation of appropriate and effective treatment against melioidosis, could worsen the outcome. Initial therapy with ceftazidime, or carbapenem with or without cotrimoxazole is recommended, followed by the oral eradication therapy (based on the antimicrobial susceptibility) with amoxicillin/clavulanic acid or cotrimoxazole. Surgical intervention remains important. This paper reviews current literature on the epidemiology, clinical features, diagnosis, and management of melioidotic bone and joint infections.